Renal Cell Carcinoma

ARON-1: IO Versus TKI for Papillary Renal Cell Carcinoma
Due to the heterogeneity of non-clear cell renal cell carcinoma (nccRCC), patients are frequently excluded from phase 3 trials focusing on clear cell RCC, resulting in limited treatment options for those with nccRCC. Francesco Massari, MD, PhD, MSc, and colleagues developed the ARON-1 study to investigate the efficacy of first-line treatment with tyrosine kinase inhibitors (TKIs) versus immuno-oncology (IO)-based combinations in patients with papillary RCC (pRCC), the most common histological subtype of nccRCC. ...
Advertisement

Latest News

Advertisement

Knowledge Hub Spotlights

Curated clinical content based on conditions, therapies, and technologies

Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma

Conference Coverage

Advertisement
Advertisement
Latest News